Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNYSE:BONNASDAQ:CRDLOTCMKTS:OPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$7.15+9.3%$5.28$3.55▼$11.16$579.92M0.582.88 million shs6.61 million shsBONBon Natural Life$1.61+2.5%$1.57$1.14▼$73.75$269K-0.471.01 million shs441,688 shsCRDLCardiol Therapeutics$1.44+2.9%$1.12$0.77▼$3.00$119.02M1.03340,742 shs289,748 shsOPTIOptec International$0.00-18.2%$0.00$0.00▼$0.00$21KN/A994,556 shs11,528 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.97%+19.13%+8.82%+25.77%+0.93%BONBon Natural Life-4.85%-19.90%+1.29%-91.46%-96.69%CRDLCardiol Therapeutics-3.45%-3.45%+23.89%+21.74%-51.05%OPTIOptec International-18.18%-18.18%-10.00%-35.71%+12.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune3.1103 of 5 stars3.52.00.00.03.43.30.6BONBon Natural LifeN/AN/AN/AN/AN/AN/AN/AN/ACRDLCardiol Therapeutics2.3466 of 5 stars3.72.00.00.03.40.00.6OPTIOptec InternationalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$20.20182.52% UpsideBONBon Natural Life 0.00N/AN/AN/ACRDLCardiol Therapeutics 3.40Buy$8.67501.85% UpsideOPTIOptec International 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BON, CRDL, ALT, and OPTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/14/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K28,995.75N/AN/A$2.75 per share2.60BONBon Natural Life$23.84M0.01$2.06 per share0.78$37.78 per share0.04CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AOPTIOptec InternationalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.26N/AN/AN/A-199,076.92%-55.81%-50.60%8/6/2025 (Estimated)BONBon Natural Life$400KN/A0.00∞N/AN/AN/AN/AN/ACRDLCardiol Therapeutics-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)OPTIOptec InternationalN/AN/A0.00∞N/AN/AN/AN/AN/ALatest BON, CRDL, ALT, and OPTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ABONBon Natural LifeN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87BONBon Natural Life0.022.422.32CRDLCardiol Therapeutics0.012.492.49OPTIOptec InternationalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%BONBon Natural Life0.57%CRDLCardiol Therapeutics12.49%OPTIOptec InternationalN/AInsider OwnershipCompanyInsider OwnershipALTAltimmune4.10%BONBon Natural Life26.48%CRDLCardiol Therapeutics5.25%OPTIOptec International50.34%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million68.21 millionOptionableBONBon Natural Life100167,000863,000Not OptionableCRDLCardiol Therapeutics2082.65 million78.27 millionNot OptionableOPTIOptec International111.65 millionN/ANot OptionableBON, CRDL, ALT, and OPTI HeadlinesRecent News About These CompaniesOptec International Inc.May 23, 2025 | barrons.comOptec Technology Ltd.April 29, 2025 | optics.orgNew Optec CEO Updates ShareholdersJanuary 16, 2025 | globenewswire.comNew Optec CEO Updates ShareholdersJanuary 16, 2025 | prismmediawire.comGlobal Optical Current Transformer Market Size Forecasted to Surpass USD 353.0 Million Valuation by 2033, Surging at 8.4% CAGRNovember 14, 2024 | fmiblog.comSITC International Expands Fleet with New Vessel OrdersOctober 30, 2024 | markets.businessinsider.comAston University researcher develops new optical technique that could revolutionise medical diagnosticsOctober 25, 2024 | eurekalert.orgbit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming TechnologyOctober 16, 2024 | standard-journal.comOptical illusion psychology test: What you see first reveals if you are optimist or too cautious in lifeOctober 4, 2024 | timesofindia.indiatimes.comOpti Digital Welcomes Guillem Fiter as Chief Marketing OfficerSeptember 17, 2024 | exchangewire.comOGP exhibiting exciting lineup of metrology systems at IMTS 2024September 6, 2024 | insights.globalspec.comAndersen Global Enters Japan with the Collaborating Firm OptiAugust 30, 2024 | tmcnet.comThe Optical Women’s Association Announces Global Connection Event at Silmo ParisAugust 29, 2024 | invisionmag.comOptical Communication and Networking Equipment Market to Reach $54.0 Billion, Globally, by 2032 at 8.7% CAGR: Allied Market ResearchAugust 20, 2024 | tmcnet.comEngineers bring efficient optical neural networks into focusAugust 15, 2024 | sciencedaily.comOptical navigation tech could streamline planetary explorationAugust 7, 2024 | msn.comIso-propagation vortices: optical multiplexing for unprecedented information capacityMay 18, 2024 | eurekalert.orgIDTechEx Release New Global Optical & Radio Frequency Metamaterials Market ReportMay 13, 2024 | tmcnet.comGlobal Optical Coherence Tomography IndustryMay 6, 2024 | fmiblog.comZeroTech Optics Appoints Lead for International SalesMay 3, 2024 | sgbonline.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in Value3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?3 High-Paying Dividend Stocks That Still Have Safe PayoutsBy Chris Markoch | May 27, 2025View 3 High-Paying Dividend Stocks That Still Have Safe Payouts3 Trades Members of Congress Are Making Right NowBy Chris Markoch | May 23, 2025View 3 Trades Members of Congress Are Making Right NowBON, CRDL, ALT, and OPTI Company DescriptionsAltimmune NASDAQ:ALT$7.15 +0.61 (+9.33%) As of 04:00 PM EasternAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Bon Natural Life NYSE:BON$1.61 +0.04 (+2.55%) As of 04:00 PM EasternBon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.Cardiol Therapeutics NASDAQ:CRDL$1.44 +0.04 (+2.86%) As of 04:00 PM EasternCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Optec International OTCMKTS:OPTI$0.0018 0.00 (-18.18%) As of 01:59 PM EasternOptec International, Inc. engages in selling and marketing optimized fuel maximizer units in North America and internationally. It markets optimized fuel maximizer for passenger vehicles, intermediate/medium duty trucks, off-road equipment, generator systems, heavy duty diesel on-road vehicles, and transportation refrigeration units. The company was formerly known as Green Meadow Products, Inc. and changed its name to Optec International, Inc. in August 2017. Optec International, Inc. was founded in 2012 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
